Navigation Links
Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.

Assignment of over 100 RNA-related Inventions a Key Step in Establishing

MDRNA as an Independent Company

BOTHELL, Wash., Dec. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has assigned (i) certain Nastech licenses to third-party intellectual property and (ii) Nastech's own intellectual property, as such intellectual property relates to the development of RNA-based therapeutics, to its subsidiary, MDRNA, Inc. ("MDRNA").

"The transfer of intellectual property rights for RNA-based therapeutics from Nastech to MDRNA is an important step in the process of creating MDRNA as an independent company. We believe MDRNA independence will ultimately enhance Nastech shareholder value," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "The MDRNA intellectual property estate includes rights to patents and patent applications covering technologies for the development and delivery of RNA-based therapeutics as well as their use in treating diseases. We believe that this agreement provides a strong foundation for MDRNA and will be important in attracting external funding for MDRNA."

About Nastech's Intellectual Property (IP)

The intellectual property estate includes rights to issued and pending patent applications relating to RNA-based therapeutics which have broad claims on their development, delivery and use in treating diseases.

The IP estate includes:

-- the building blocks for drugs, including novel nucleotides, cationic

lipids, and formulations;

-- the RNA drug cargo, i.e., RISC and Dicer substrate constructs;

-- delivery chemistry, both covalent conjugates and co

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nastech to Host 2007 Analyst and Institutional Investor Day
2. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
3. Nastech Announces Third Quarter 2007 Financial Results
4. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
5. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
6. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
7. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
8. New property found in ancient mineral lodestone
9. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... and partnering meetings taking place in the month of ... – Partnering Forum RepliCel will be presenting at ... Meeting on the Mesa to be held October 7-9 ...
(Date:10/8/2015)... Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... brand within its Applied Diagnostics and Testing ... reference standards product line with ten certified Snap-N-Spike ... bile acids and their stable-labeled internal standards. These ... lithocholic acid, taurocholic acid and native and deuterium-labeled ...
(Date:10/8/2015)... TORONTO, CANADA (PRWEB) , ... October 08, 2015 ... ... it has entered into an exclusive license agreement to develop and commercialize intellectual ... expands upon the original agreement from February 2009, and affords exclusive worldwide rights ...
(Date:10/7/2015)... 8, 2015 ... accounts for largest bioinformatics market share due ... discovery and development process says this research ... . --> ... of applications, the bioinformatics market is segmented ...
Breaking Biology Technology:
... 2011 Reliv International , Inc. (NASDAQ: RELV), ... today announced a new joint research and development partnership ... soy and plant biotechnology research. "The partnership ... the nation,s leading biotech researchers to develop new nutritional ...
... Fla., Aug. 23, 2011 Biotechnology leader Divine Skin ... in the second quarter. The expanding innovator of personal ... backorders and accelerating sales, which are 79 percent ahead ... of our challenges has been keeping up with demand," ...
... China Cord Blood Corporation (NYSE: CO ) ("the ... the first quarter of fiscal year 2012 on Monday, August ... The Company will hold a conference call at 8:00 a.m. ... performance and give a brief overview of the Company,s recent ...
Cached Biology Technology:
(Date:9/29/2015)... Calif. , Sept. 29, 2015 ... improves employee productivity while also saving energy , ... such as Low Power Active Mode and embedded Fujitsu ... transformation Fujitsu today shows that good ... new and refreshed models to its enterprise desktop and ...
(Date:9/28/2015)... , September 28, 2015 According ... (Hardware & Software), Product (Scanner & Others), Application (Access ... Defense, & Others) & Geography Global - Forecast to ... to reach USD 3627.90 Million by 2020, at a ... Browse 65 market data T ables and ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
Breaking Biology News(10 mins):
... two genes already known to control cell movement are ... findings in the April issue of Developmental Cell. , ... for a dividing cell's halves to separate, raising the ... stopping the uncontrolled cell division found in cancers. Mutations ...
... to the development of certain types of cancer, ... well understood. A new research study published in ... lymphocytes as important regulators of premalignancy associated with ... against B lymphocytes or recruitment of innate immune ...
... University Medical Center have shown that a commonly used ... a heart attack does not improve patient outcomes. , ... successfully used during angioplasty in vein grafts and stenting ... 2 issue of the Journal of the American Medical ...
Cached Biology News:
Rab GDP dissociation inhibitor beta...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... sequencing inserts cloned into M13/pUC-based plasmids, plasmids ... polymerase promoters, or lambda gt10 and gt11 ... of 0.1 µg/µl in water. The primers ... using SequiTherm™ EXCEL™ II DNA Polymerase with ...
Biology Products: